KCI and LifeCell purchase adipose tissue injector

KCI has announced that its sister brand LifeCell has acquired rights to a new adipose tissue injector (aTI) device from the TauTona Group, a California-based medical device incubator.

The aTI is designed for use in improved fat grafting procedures and is a battery-powered, single-use tool that delivers fat at a controlled rate, reducing the complexity of performing injections and allowing the surgeon to focus on placement.

By managing the pressure and flow rates during injection, the aTI minimises damage to the injected fat and efficiently delivers the tissue to the injection site. It represents the second product in the LifeCell fat grafting portfolio.

It will help to expand the company's offering for reconstructive and cosmetic procedures utilising fat grafting technology, following the launch of the Revolve Fat Processing System in October 2013.

Philip Croxford, senior vice-president at LifeCell, said: "The acquisition of the adipose tissue injector demonstrates our ongoing commitment to providing clinicians with the tools they need to provide efficient, cost-effective surgical and reconstructive procedures to their patients."

KCI and LifeCell merged into a single company last year alongside the recently acquired Systagenix, a move designed to foster collaboration and increase innovation across different platforms.